LiverLearning®: 2021 Liver Cancer SIG: Advances in Molecular Therapies and Emerging Treatment in Advanced HCC

Hepatocellular carcinoma (HCC) management strategies have been revolutionized over the last five years. Combination therapies are now standard of care for advanced HCC patients, and novel emerging therapies are currently being tested and approved. At this exciting talk, experts will review the many opportunities to improve management, quality of life and outcomes of patients with advanced HCC.

LiverLearning®: 2021 General Hepatology Update

What pressing challenges do patients with advanced liver disease and/or liver cancer face as they consider treatment options with their physicians? Complex diseases must be managed by a multidisciplinary team to achieve optimal outcomes. At this program, faculty will review effective strategies to incorporate multidisciplinary approaches in the management of liver cancer, portal hypertension, and substance-use disorders.

LiverLearning®: 2021 AASLD/ASGE Endoscopy Course: Clinical Challenges and Practical Solutions at the Interface of Liver Disease and Endoscopy

The 2021 AASLD/ASGE Endoscopy Course at AASLD will foster discussions on the management of challenging clinical scenarios encountered by hepatologists and gastroenterologists that require endoscopic consideration. This evidence-based course includes expert opinions on potential knowledge gaps or clinical controversies. The session has a case-based, interactive format that emphasizes good clinical practice, emerging paradigms, innovation, and safety concerns.

LiverLearning®: 2021 Clinical Research Workshop - Part I and II: Basics of Navigating Artificial Intelligence in Liver Research

To introduce artificial intelligence in the management of liver disease for clinicians. This program spans several applications of AI in hepatology spanning administrative datasets, radiology, pathology and multi-omics. This interactive session will spur further dialogue and research into this field and provide a platform to build on for future CRW events.

The Impact of Median Model for End‐Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma

Sarah Bernards, Ryutaro Hirose, Francis Y. Yao, Chengshi Jin, Jennifer L. Dodge, Chiung‐Yu Huang, Neil Mehta – 10 November 2021 – As a result of ongoing regional disparities, the United Network for Organ Sharing (UNOS) implemented policy in May 2019 limiting exception points for waitlisted patients with hepatocellular carcinoma (HCC) to median Model for End‐Stage Liver Disease at transplant in the area surrounding a transplant center minus 3 points (MMAT‐3). The impact of this policy change remains unknown.

Subscribe to